Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions
able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently
needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the
proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to
treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal,
IAV-specific immunity following vaccination.